Osaka University

Daiichi Sankyo Company, Limited

Anges Mg, Inc.

Yoshiaki Taniyama

Ryuichi Morishita

Naruto Katsuragi

Fumihiro Sanada

Toshio Ogihara

Junya Azuma

Provided is a pharmaceutical composition for the treatment of a disease associated with upregulated periostin expression or periostin splice variant switching, which pharmaceutical composition comprises, as an active ingredient, a nucleic acid capable of inducing skipping of exon 17 in periostin gene transcription and/or a nucleic acid capable of inducing skipping of exon 21 in periostin gene transcription. The pharmaceutical composition of the present invention can treat a disease associated with upregulated periostin expression or periostin splice variant switching, while preventing complete inhibition of the functions of periostin.

Pharmaceutical composition for treatment of diseases associated with upregulated periostin expression or periostin splice variant switching

The present invention provides a drug for preventing or treating inflammation-associated diseases in which a periostin isoform having cell adhesion activity is involved, and also provides an inhibitor of a periostin isoform having cell adhesion activity.

Antibody against peptide encoded by Exon-21 of periostin and pharmaceutical composition for preventing or treating inflammation-associated diseases containing the same

The present invention provides an antibody against a periostin isoform having anti-cell adhesive activity, especially an anti-periostin antibody having the ability to neutralize anti-cell adhesive properties, as well as a prophylactic or therapeutic agent for periostin-related diseases comprising the antibody. The present invention also provides methods for detecting and quantifying the periostin isoform in a sample by using the antibody, as well as a method for diagnosing periostin-related diseases comprising measuring the amount of the periostin isoform by the detection or quantification method.

Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved

This invention enables the repair of cardiac function by noninvasive administration of an HGF gene in the form of Sendai virus (HVJ)-liposome into the affected cardiac muscle, thereby inducing angiogenesis of the cardiac muscle layer and repressing fibrosis.

Growing community of inventors

Osaka, Japan

Yoshiaki Taniyama